The Rowley Prize is awarded each year by the iCMLf to an individual who has made an outstanding lifetime contribution to our understanding of the biology of CML. The Rowley Prize was awarded for the first time in 2009 to Dr Brian Druker, followed by Dr Moshe Talpaz (2010), Dr John Goldman (2011), Dr George Q Daley (2012), Dr Connie Eaves (2013), Dr. Owen Witte (2014), Dr Rick Van Etten (2015), Professors John Groffen and Nora Heisterkamp (2016) and Professor Tessa Holyoake in 2017.
Dr Janet Rowley kindly gave the iCMLf permission to name this prestigious award in her honour. Prior to her death in December 2013, Dr Rowley was the Blum-Riese Distinguished Service Professor of Medicine, Molecular Genetics and Cell Biology and Human Genetics at the University of Chicago. In 1973 she made a seminal discovery in CML when she used newly developed chromosome banding techniques to show that the Philadelphia chromosome is formed by a translocation between chromosomes 9 and 22. This discovery led to the eventual identification of the fusion gene BCR-ABL and ultimately to the development of targeted inhibitors of this leukemia-specific oncoprotein. This is one of many major contributions made by Dr Rowley and her team to our understanding of the molecular biology of leukemia and other cancers. She was recently awarded the Presidential Medal of Freedom, the highest civilian honour awarded in the USA.
The iCMLf Goldman Prize complements the Rowley Prize as a clinical equivalent by recognising lifetime contributions to the management of patients with CML. This award has been created in memory of the late iCMLf chair, John Goldman, to honour his commitment to clinical excellence in treating CML. John Goldman was an outstanding scientist with a worldwide recognition and a leading figure in CML research. During his career of over 40 years he made major contribution to the understanding of the biology and the treatment of CML. He made seminal contributions to a variety of breakthroughs in CML research particularly in the field of stem cell transplantation, in the clinical development of new therapies and in the advancements of diagnostics. He was the first to demonstrate the presence of stem cells in the peripheral blood of CML patients and their potential role in autografting patients with CML. He also pioneered allogeneic stem cell transplant for CML in Europe. John Goldman played a distinctive and visionary role for the iCMLf as one of its co-founders and sitting chair at the time of his death. The Goldman Prize was awarded for the first time in 2014 to Professor Rüdiger Hehlmann, he was followed by Michele Bacarrani (2015), Professor Hagop Kantarjian (2016) and Professor Tim Hughes as the Prize recipient in 2017.
In 2015 the iCMLf introduced a new prize. The iCMLf Prize is awarded annually by the iCMLf to recognise outstanding contributions to the improvement of CML treatment in the emerging economic regions. The iCMLf Prize was formerly named the ERSAP (Emerging Regions Support and Partnership Prize) and was first awarded in 2015 to Pat Garcia-Gonzalez, CEO of The Max Foundation. She was followed by Associate Professor Susan Branford in 2016. The 2017 prize is awarded to Professor Jerry Radich.